BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 49 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $748,132 | -83.2% | 771,000 | -83.0% | 0.00% | -80.0% |
Q2 2023 | $4,455,753 | -4.0% | 4,530,000 | 0.0% | 0.02% | -6.2% |
Q1 2023 | $4,643,069 | -4.1% | 4,530,000 | 0.0% | 0.02% | -5.9% |
Q4 2022 | $4,841,438 | -67.2% | 4,530,000 | -69.5% | 0.02% | -41.4% |
Q3 2022 | $14,746,161 | +0.3% | 14,860,000 | 0.0% | 0.03% | +7.4% |
Q2 2022 | $14,707,917 | -13.2% | 14,860,000 | -11.9% | 0.03% | +12.5% |
Q1 2022 | $16,935,851 | +90.2% | 16,860,000 | +100.0% | 0.02% | +4.3% |
Q4 2021 | $8,906,000 | -19.0% | 8,430,000 | -20.4% | 0.02% | -25.8% |
Q3 2021 | $10,997,000 | -50.3% | 10,590,000 | -50.0% | 0.03% | -3.1% |
Q2 2021 | $22,132,000 | +99.2% | 21,180,000 | +100.0% | 0.03% | -5.9% |
Q1 2021 | $11,110,000 | -2.1% | 10,590,000 | 0.0% | 0.03% | -5.6% |
Q4 2020 | $11,354,000 | +28.0% | 10,590,000 | +27.3% | 0.04% | +12.5% |
Q3 2020 | $8,867,000 | +21.7% | 8,320,000 | +39.6% | 0.03% | +128.6% |
Q2 2020 | $7,284,000 | – | 5,960,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 16,732,000 | $16,408,385 | 1.23% |
SONA ASSET MANAGEMENT (US) LLC | 23,125,000 | $22,451,923 | 0.93% |
SSI INVESTMENT MANAGEMENT LLC | 8,726,000 | $8,464,220 | 0.69% |
PFM Health Sciences, LP | 15,000,000 | $14,587,500 | 0.69% |
RWC Asset Management LLP | 10,000,000 | $9,709,000 | 0.63% |
Sonora Investment Management Group, LLC | 6,245,000 | $6,108,182 | 0.52% |
Paloma Partners Management Co | 10,006,000 | $9,733,285 | 0.34% |
MACKAY SHIELDS LLC | 9,891,000 | $9,594,270 | 0.26% |
PALISADE CAPITAL MANAGEMENT, LP | 8,704,000 | $8,455,066 | 0.24% |
Centiva Capital, LP | 10,000,000 | $9,716,288 | 0.21% |